Gefitinib Inhibition of Drug Resistance to Doxorubicin by Inactivating ABCG2 in Thyroid Cancer Cell Lines
Authors:
- Jay Patrick LopezJLJay Patrick Lopez
- Jessica Wang-RodriguezJWJessica Wang-Rodriguez
- Catherine ChangCCCatherine Chang
- Jocelyn S. ChenJCJocelyn S. Chen
- Francisco S. PardoFPFrancisco S. Pardo
- Joseph AguileraJAJoseph Aguilera
- Weg M. OngkekoWOWeg M. Ongkeko
Open Access
- 1 October 2007
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 133 (10) , 1022-1027
Abstract
Thyroid cancer accounts for most deaths from endocrine malignant neoplasms. Most thyroid cancers can be successfully managed by surgical resection with or without radioactive iodine ablation. However, a subset of thyroid cancers, including anaplastic thyroid cancer (ATC) and metastatic follicular thyroid cancer (FTC), can be very aggressive and resistant to therapy, often leading to death. For ATC, the traditional and mainstay treatment has been the use of doxorubicin hydrochloride, a quinone-containing anthracycline, but this treatment has proven to be ineffective primarily because of drug resistance.1,2 More recently, combination drug treatments using doxorubicin, cisplatin, and paclitaxel have been used, but none of these have shown notable promise.3 Even with the combination of surgery, radiotherapy, and chemotherapy, a diagnosis of ATC is linked to high rates of mortality with a mean survival of 4 to 12 months.4-6 Likewise, metastatic FTC carries a poor prognosis owing to the limited avenues for treatment that are currently available. Although differentiated thyroid cancers usually result in a high probability of long-term survival, this is not true once distant metastases is present: the 10-year survival rate is less than 20%.7,8 Furthermore, patients who have metastatic FTC to the bone can also experience considerable morbidity from pathologic fractures, spinal cord compression, and severe pain. With the steady increase in the incidence of thyroid cancer in the United States9 coupled with the dismal treatment options currently available for ATC and metastatic FTC, a better understanding of these malignant neoplasms as well as more effective treatment options are clearly indicated.Keywords
This publication has 17 references indexed in Scilit:
- EGFR Regulates the Side Population in Head and Neck Squamous Cell CarcinomaThe Laryngoscope, 2006
- Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment ApproachesAnnals of Surgical Oncology, 2006
- Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell linesBritish Journal of Cancer, 2005
- Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid CancerClinical Cancer Research, 2004
- Epidermal Growth Factor Receptor as a Novel Therapeutic Target in Anaplastic Thyroid CarcinomasAnnals of the New York Academy of Sciences, 2004
- A New Method of Predicting US and State-Level Cancer Mortality Counts for the Current Calendar YearCA: A Cancer Journal for Clinicians, 2004
- Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgeryBritish Journal of Cancer, 2002
- Combination therapy for anaplastic giant cell thyroid carcinomaCancer, 1991
- Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 casesCancer, 1990
- Long-Term Results of Treatment of 283 Patients with Lung and Bone Metastases from Differentiated Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 1986